|
GB0816096D0
|
|
Diabetes t cell receptors
|
|
GB0812380D0
|
|
High affinity Gp100 T cell receptors
|
|
GB0806238D0
|
|
T cells presenting modified cd8
|
|
GB0804032D0
|
|
Cellular peptide-MHC assay
|
|
GB0801911D0
|
|
Tcell receptor-based hypersensitivity therapeutics
|
|
GB0801910D0
|
|
Tcellrecepter-based hypersensitivity therapeutics
|
|
WO2009060159A1
|
|
Mutated ilt molecules
|
|
WO2008038002A2
|
|
T cell therapies
|
|
CA2670446A1
|
|
Ilt-2 (liri) variants with increased affinity for mhc class i molecules
|
|
WO2008037943A1
|
|
Cells transformed with nucleic acid encoding ny-eso t cell receptors
|
|
EP1899374A1
|
|
Synthetic ligands of peptide-mhc complexes, or cd1-antigen complexes
|
|
NZ541973A
|
|
Immunomodulating heterocyclic compounds
|
|
NZ539226A
|
|
T cell receptor display
|
